^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    silodosin

    Company:
    Generic mfg.
    Drug class:
    α1 adrenergic receptor antagonist
    10d
    Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy (clinicaltrials.gov)
    P3, N=148, Completed, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Completed
    Trial completion
    |
    silodosin
    22d
    Comparative Study for Medical Therapy for Lower Ureteral Stones (clinicaltrials.gov)
    P3, N=180, Completed, Beni-Suef University
    New P3 trial
    |
    silodosin
    11ms
    Silodosin in Retrograde Intrarenal Surgery (clinicaltrials.gov)
    P3, N=60, Completed, Ain Shams University | Enrolling by invitation --> Completed
    Trial completion
    |
    silodosin
    1year
    Silodosin vs Placebo in the Treatment of Female LUTS (clinicaltrials.gov)
    P3, N=278, Not yet recruiting, Mansoura University
    New P3 trial
    |
    silodosin
    1year
    Prophylactic Α-Blockers for Radiotherapy-Induced LUTS in Men with Prostate Cancer: A Phase III Randomized Trial Analysis. (PubMed, Int J Radiat Oncol Biol Phys)
    Prophylactic α-blocker was not effective at significantly reducing RI-LUTS in prostate cancer patients treated with EBRT. Treating patients with α-blocker at the onset of RI-LUTS will avoid unnecessary drug exposure and toxicity. There may be a benefit for prophylactic α-blocker in patients with smaller prostate. This however, needs to be further studied in a larger study.
    P3 data • Journal
    |
    silodosin
    over1year
    Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial. (PubMed, Cancers (Basel))
    Prophylactic α-blockers were not effective at significantly reducing RI-LUTSs in prostate cancer patients treated with EBRT. Treating patients with α-blockers at the onset of RI-LUTSs will avoid unnecessary drug exposure and toxicity.
    P3 data • Journal
    |
    silodosin